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PATZ1 is a ubiquitously expressed transcriptional repressor belonging to the
ZBTB family that is functionally expressed in T lymphocytes. PATZ1 targets the
CD8 gene in lymphocyte development and interacts with the p53 protein to
control genes that are important in proliferation and in the DNA-damage
response. PATZ1 exerts its activity through an N-terminal BTB domain that
mediates dimerization and co-repressor interactions and a C-terminal zinc-
finger motif-containing domain that mediates DNA binding. Here, the crystal
structures of the murine and zebrafish PATZ1 BTB domains are reported at 2.3
and 1.8 A˚ resolution, respectively. The structures revealed that the PATZ1 BTB
domain forms a stable homodimer with a lateral surface groove, as in other
ZBTB structures. Analysis of the lateral groove revealed a large acidic patch in
this region, which contrasts with the previously resolved basic co-repressor
binding interface of BCL6. A large 30-amino-acid glycine- and alanine-rich
central loop, which is unique to mammalian PATZ1 amongst all ZBTB proteins,
could not be resolved, probably owing to its flexibility. Molecular-dynamics
simulations suggest a contribution of this loop to modulation of the mammalian
BTB dimerization interface.
1. Introduction
PATZ1 (POZ-, AT hook- and zinc-finger-containing protein
1), also known as ZBTB19, is a transcription factor that is
present in all vertebrates (Fig. 1a). It was first discovered in a
yeast two-hybrid (Y2H) experiment, in which it associated
through its BTB (broad complex, tramtrack and bric-a-brac)
domain with the BTB domain of the transcription factor
BACH2 (BTB and CNC homology 2; Kobayashi et al., 2000).
PATZ1 is also referred to as MAZR (Myc-associated zinc
finger-related) because of the close similarity between its zinc-
finger (ZF) domain and that of MAZ (Myc-associated zinc
finger). While its expression can be detected in many cell types
and developmental stages, PATZ1/ZBTB19/MAZR is highly
expressed specifically in the early stages of T-lymphocyte
differentiation, where it negatively regulates CD8 gene
expression (Bilic & Ellmeier, 2007). PATZ1 has been shown to
participate in thymocyte development and CD4, CD8 and Treg
lineage choice by repressing the expression of ThPOK
(ZBTB7B/ZBTB15/cKrox), another BTB domain-containing
transcription factor (Sakaguchi et al., 2010, 2015; He et al.,
2010), and the expression of the FOXP3 transcription factor
(Andersen et al., 2019). The functions of PATZ1 are however
not limited to lymphocytes as its expression is ubiquitous.
An early embryonic role for PATZ1 has been suggested, as
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Figure 1
Sequence alignment of BTB domains of ZBTB transcription factors identifies a unique central region in PATZ1 that is conserved in mammals. (a)
Sequence alignment of PATZ1 BTB domains from selected vertebrate species. The unique central sequence of the A2/B3 loop that is conserved in
mammals and is missing in fish and amphibians is indicated in bold. (b) Sequence alignment of selected human ZBTB proteins and their predicted
secondary structure. The sequences of the human PATZ1 and cKrox BTB domains with their unique extra region between the A2 helix and B3 strand are
shown above. The PATZ1 amino acids that correspond to this region without electron-density assignments from the crystal structure are shown in bold.
Arrows and rods identify predicted conserved -strand and -helical regions. The eight BTB domains with solved structures are annotated on the left
with their common names in addition to the ZBTB nomenclature. Shading, asterisks, colons and periods identify conserved residues according to the
Clustal format. A consensus sequence is shown at the bottom, with the three predicted degron residues involved in BTB domain stability indicated by
arrows.
PATZ1/ mice are embryonic lethal or born at non-
Mendelian frequency and are small in size depending on the
genetic background (Sakaguchi et al., 2010). PATZ1 also
negatively regulates induced pluripotent stem-cell (iPSC)
generation (Ow et al., 2014; Ma et al., 2014). This function may
be related to its interaction with the p53 tumour suppressor, as
demonstrated by various studies (Valentino, Palmieri, Vitiello,
Pierantoni et al., 2013; Keskin et al., 2015; Chiappetta et al.,
2015).
Structurally, PATZ1 belongs to the POZ (pox virus and zinc
finger) or ZBTB (zinc finger and BTB) family of transcription
factors (Lee &Maeda, 2012). Proteins belonging to this family
have been implicated in many biological processes, including
transcriptional regulation and development (Chevrier &
Corcoran, 2014), whilst their dysfunction in vertebrates has
been linked to tumorigenesis. ZBTB proteins bind to DNA
through their ZF domains, and use their BTB domains for
oligomerization (Bonchuk et al., 2011) and the recruitment of
co-repressors and chromatin-remodelling factors (Bardwell &
Treisman, 1994; Siggs & Beutler, 2012). The human genome
encodes 49 members of the ZBTB family (Fig. 1b), all of which
contain an N-terminal BTB domain and a variable number of
ZF motifs at their C-terminus. Two members of this family
contain an additional motif in the form of an AT hook (PATZ1
and PATZ2/ZBTB24).
The BTB domain is a structural feature that mediates
functional interactions between proteins (Perez-Torrado et al.,
2006). Most of the available BTB domain structures from the
ZBTB family are homodimers formed by the assembly of two
identical monomers (Ahmad et al., 1998, 2003; Li et al., 1999;
Schubot et al., 2006; Stogios et al., 2007, 2010; Ghetu et al.,
2008; Stead et al., 2008; Cerchietti et al., 2010; Sakamoto et al.,
2017; McCoull et al., 2017, 2018; Kamada et al., 2017; Yasui et
al., 2017; Kerres et al., 2017; Cheng et al., 2018). In the case of
Myc-interacting zinc-finger protein 1 (MIZ1), the structures of
both a homodimer (Stogios et al., 2010) and a homotetramer
(Stead et al., 2007) have been reported.
The overall fold of the BTB domain is highly conserved,
containing the following secondary-structure elements: 1–
1–B1–B2–A1–A2–B3–A3–2–A4–A5 (Stogios et al., 2005).
A unique feature of the PATZ1 BTB domain is a long glycine-
and alanine-rich central loop between A2 and B3 (Kobayashi
et al., 2000; Fig. 1). This central loop is conserved in all
vertebrate PATZ1 proteins, but it is absent in those from fish
and amphibians. The two BTB monomers are known to
homodimerize through a specific dimerization interface that
includes 1–1, A1–A2 and 2–A5. Although homo-
dimerization seems to be favoured, heterodimeric interactions
between pairs of ZBTB proteins have also been documented.
The crystal structure of a tethered ‘forced’ heterodimer
between the BTB domains of MIZ1 and B-cell lymphoma 6
protein (BCL6) suggests that heterodimers can use the same
interface as homodimers (Stead & Wright, 2014). Together
with BCL6, MIZ1 seems to be a promiscuous member of the
ZBTB family, making more heterodimers than any other BTB
domain. MIZ1 functionally interacts with BCL6 in germinal
centre B cells (Phan et al., 2005), ZBTB4 (Weber et al., 2008),
ZBTB36 (Lee et al., 2012), ZBTB49 (Jeon et al., 2014) and
NAC1 (nucleus accumbens-associated 1; Stead & Wright,
2014). PATZ1 can also form heterodimers with other BTB-
domain-containing proteins such as PATZ2 (Huttlin et al.,
2015), BACH1 and BACH2 (Kobayashi et al., 2000).
The mechanism controlling the homodimerization versus
heterodimerization of BTB domains has not been elucidated.
Co-translational dimerization, a mechanism often required in
protein-complex assembly, may be at play (Kramer et al.,
2019). Recently, a dimerization quality-control mechanism for
BTB proteins has been proposed in which the stability of a
homodimer would exceed that of heterodimers because of the
structural masking of destabilizing residues (Herhaus & Dikic,
2018; Mena et al., 2018). According to this model, the
preferential exposure of three ‘degron’ residues on BTB
heterodimers results in targeting by ubiquitin ligases and a
shorter half-life. Whether this mechanism is universally shared
by all BTB domain-containing proteins, including members of
the ZBTB family, remains unclear.
Homodimerization of BCL6 and promyelocytic leukaemia
zinc-finger (PLZF) proteins creates a charged groove that
binds nuclear receptor co-repressors such as NCOR1, NCOR2
(SMRT) and BCOR (Huynh & Bardwell, 1998; Wong &
Privalsky, 1998; Huynh et al., 2000; Melnick et al., 2000, 2002).
NCOR1 and SMRT are structurally disordered proteins that
share 45% identity (Granadino-Rolda´n et al., 2014) and
contain a conserved 17-amino-acid BCL6-binding domain
(BBD). These co-repressors are components of large
complexes containing histone deacetylases (Li et al., 2000) that
contribute to transcriptional silencing. It is not known whether
co-repressor binding is a generalizable feature of BTB
homodimers, as MIZ1, FAZF and LRF BTB homodimers do
not interact with these co-repressors (Stogios et al., 2007,
2010). The PATZ1 BTB domain has been shown to interact
with NCOR1; however, it is not known whether the inter-
action is mediated by an interface similar to that of BCL6 and
PLZF (Bilic et al., 2006).
Prior to this work, the structures of eight different proteins
belonging to the ZBTB family were available in the Protein
Data Bank (PDB): LRF/Poke´mon (ZBTB7A), PLZF
(ZBTB16), MIZ1 (ZBTB17), BCL6 (ZBTB27), MYNN
(ZBTB31), FAZF (ZBTB32), KAISO (ZBTB33) and HKR3/
TZAP (ZBTB48). In order to obtain biological insights into
the binding of PATZ1 to co-repressors, we determined the
atomic structure of the PATZ1 (ZBTB19) BTB domain. To
probe the role of the unique A2/B3 central loop, we obtained
crystal structures of both the mouse PATZ1 BTB domain and
its zebrafish orthologue.
2. Materials and methods
2.1. Protein expression and purification
The human isoform 3 (Q9HBE1-3) and mouse (Q9JMG9)
PATZ1 BTB sequences are 98.9% identical (as determined
using LALIGN; Gasteiger et al., 2003), diverging at only one
residue (T91A). The mouse PATZ1 BTB protein-coding
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sequence (12–166) was PCR-amplified from a CMV-HA
plasmid construct (Keskin et al., 2015) containing the full-
length mouse PATZ1 cDNA and cloned into a pET-47b
bacterial expression plasmid (Novagen) between SmaI and
NotI restriction sites in frame with an N-terminal 6His tag
and an HRV 3C protease cleavage site for fusion-tag removal.
The resulting plasmid was transformed into the Escherichia
coli Rosetta 2(DE3) strain and grown at 310 K by shaking at
180 rev min1 in Terrific/Turbo Broth (TB) medium supple-
mented with 50 mg ml1 kanamycin and 33 mg ml1 chloram-
phenicol until the absorbance at 600 nm reached a value of 0.6.
Expression of the fusion protein was induced by the addition
of 0.1 mM isopropyl -d-1-thiogalactopyranoside (IPTG) and
growth was continued for 16 h at 291 K. The zebrafish (Danio
rerio) PATZ1 BTB protein-coding sequence (1–135) was
PCR-amplified from zebrafish genomic DNA (a kind gift from
Dr S. H. Fuss), cloned and expressed in the same bacterial
expression plasmid as described above.
The cells were harvested by centrifugation, resuspended in
25 ml lysis buffer (50 mMHEPES pH 7, 250 mMNaCl, 10 mM
imidazole, 0.5 mM TCEP, DNase and protease-inhibitor
cocktail) and disrupted by sonication on ice. The lysate was
clarified by centrifugation at 26 700g for 45 min at 277 K. The
supernatant was applied onto a HisPur Cobalt Resin column
(Thermo Fisher) previously equilibrated with wash buffer
(50 mM HEPES, 250 mM NaCl, 0.5 mM TCEP, 10 mM
imidazole). Following a 10 min incubation at 227 K and the
application of wash buffer, the protein was then eluted by the
addition of elution buffer (50 mM HEPES, 250 mM NaCl,
0.5 mM TCEP, 300 mM imidazole). The collected eluate was
concentrated to 2.6 mg ml1 using a Sartorius Vivaspin 20
column (10K molecular-weight cutoff) for additional purifi-
cation by size-exclusion chromatography (SEC) using a
HiLoad 16/600 Superdex 75 prep-grade column (GE Health-
care) in gel-filtration buffer (20 mM HEPES, 250 mM NaCl,
0.5 mM TCEP) at 277 K. Fractions were analyzed on a 14%
SDS–PAGE gel by electrophoresis and those containing
PATZ1 BTB were pooled and concentrated to 9 mg ml1. The
zebrafish PATZ1 BTB domain (69% sequence identity to
mouse BTB) was expressed and purified as described above
for the mouse BTB domain. The final concentration of the
protein was 8.5 mg ml1.
2.2. Crystallization
All crystallization experiments were performed at 291 K
using the sitting-drop vapour-diffusion method. The initial
screening of 768 conditions was performed at the University of
Sussex crystallization facility using a Crystal Phoenix dispen-
sing robot to pipette 0.1 ml protein solution and 0.1 ml
precipitant solution into single drops in 96-well plates. Crystals
of the mouse PATZ1 BTB domain appeared after 72 h
in 0.1M MMT (dl-malic acid, MES monohydrate, Tris),
25%(w/v) PEG 1500. Crystals of the zebrafish PATZ1 BTB
domain appeared after 72 h in 40%(v/v) PEG 500 MME,
20%(w/v) PEG 20K, 0.1M Tris pH 8.5, 0.06M magnesium
chloride hexahydrate, 0.06M calcium chloride dihydrate.
2.3. Data collection and processing
For data collection, single crystals were briefly immersed in
mother liquor supplemented with 20% glycerol prior to flash-
cooling in liquid nitrogen. For mouse PATZ1 BTB, data were
collected to 2.29 A˚ resolution on beamline I04 at Diamond
Light Source, Didcot, UK. The diffraction data were indexed,
integrated, scaled and reduced with xia2 (Winter, 2010) and
AIMLESS (Evans & Murshudov, 2013). The space group was
P41212 (unit-cell parameters a = b = 43.23, c= 162.95 A˚, =  =
 = 90), with one molecule in the asymmetric unit.
For zebrafish PATZ1 BTB, data were collected to 1.8 A˚
resolution on beamline I04 at Diamond Light Source. The
diffraction data were indexed, integrated, scaled and reduced
with xia2 andXDS (Kabsch, 2010). The space group was P3121
(unit-cell parameters a=b= 43.08, c= 123.64 A˚,==  = 90),
with one molecule in the asymmetric unit.
Detailed X-ray data-collection and refinement statistics are
given in Table 1.
2.4. Structure solution and refinement
The structure of mouse PATZ1 BTB was solved by mole-
cular replacement with Phaser (McCoy et al., 2007) using the
PLZF BTB structure (PDB entry 1buo; Ahmad et al., 1998) as
a search template. The identified solution was then subjected
to rounds of manual rebuilding with Coot (Emsley et al., 2010)
and refinement with Phenix (Liebschner et al., 2019) to give
final Rwork and Rfree factors of 20.9% and 24.5%, respectively.
The final structure was validated withMolProbity (Williams et
al., 2018) and deposited together with the structure factors in
the Protein Data Bank as entry 6guv.
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Table 1
Data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Mouse PATZ1 BTB Zebrafish PATZ1 BTB
Data-collection statistics
Wavelength (A˚) 0.97625 0.9795
Space group P41212 P3121
a, b, c (A˚) 43.23, 43.23, 162.95 43.08, 43.08, 123.64
, ,  () 90, 90, 90 90, 90, 120
Resolution (A˚) 43.23–2.29 (2.37–2.29) 41.8–1.8 (1.9–1.8)
No. of unique reflections 7573 (724) 12786 (1120)
Rmerge 0.05 (0.67) 0.01 (0.49)
hI/(I)i 9.91 (1.39) 19.96 (1.27)
Completeness (%) 99.58 (99.18) 98.41 (87.99)
Multiplicity 2.0 (2.0) 2.0 (1.8)
Refinement statistics
Resolution (A˚) 41.79–2.29 41.2–1.8
No. of reflections
(observed/Rfree)
7549/417 12785/571
Rwork/Rfree 0.209/0.245 0.215/0.224
No. of atoms
Total 1123 993
Protein 1057 940
Water 66 53
Average B, all atoms (A˚2) 54.3 50
R.m.s. deviations
Bond lengths (A˚) 0.002 0.007
Bond angles () 0.433 0.965
PDB code 6guv 6guw
The structure of zebrafish PATZ1 BTB was solved by
molecular replacement with Phaser using the mouse PATZ1
BTB structure (PDB entry 6guv) as the search template. The
identified solution was then subjected to rounds of manual
rebuilding with Coot and refinement with Phenix to give final
Rwork and Rfree factors of 21.5% and 22.4%, respectively. The
final structure was validated with MolProbity and deposited
together with the structure factors in the Protein Data Bank as
entry 6guw.
Detailed X-ray data-refinement statistics are given in
Table 1.
2.5. Sequence and structure analysis
The sequences of PATZ1 proteins from different organisms
were retrieved from the NCBI Reference Sequence Database
(RefSeq; Pruitt et al., 2007). Except for Homo sapiens
(NP_114440.1) and Mus musculus (NP_001240620.1) for
mammals, one organism only was chosen for each group of
different species of vertebrates:Danio rerio (XP_009300883.1)
for fish, Xenopus laevis (XP_018117120.1) for amphibians,
Thamnophis sirtalis (XP_013922905.1) for reptiles and Parus
major (XP_015499085.1) for birds. Sequence limits were
determined based on the annotations of the BTB domain in
the UniProt database (The UniProt Consortium, 2019). The 49
members of the human ZBTB protein family were retrieved
from Swiss-Prot and a multiple sequence alignment was
obtained using the PROMALS3D online tool (Pei et al., 2008).
This alignment incorporates the structural information from
the available PDB structures of these proteins. The secondary-
structure nomenclature refers to that of Stogios et al. (2005)
(Figs. 1b, 2a, 2c and 2f). ZBTB4 was excluded from this
alignment because of its N-terminal serine-rich repetitive
insertions, which are beyond the scope of this description.
Shading was added according to the percentage of similarity
for every position in the alignment visualized in Jalview 2
(Waterhouse et al., 2009) that generated a consensus sequence.
A list of residues involved in homodimer interaction interfaces
was obtained by PDBePISA (Krissinel & Henrick, 2007) and
was graphically rendered on the protein structure with VMD
(Humphrey et al., 1996). Intra-chain and inter-chain inter-
actions were retrieved by PIC (Protein Interactions Calculator;
Tina et al., 2007) and the VMD Salt Bridges and Timeline
plugins. Structural alignments were calculated using the
MultiProt server (Shatsky et al., 2004).
2.6. Modelling
The central loop of the mammalian PATZ1 BTB structure
(residues 83–113) was modelled as a monomer using the
PRIMO suite (Hatherley et al., 2016) based on the
MODELLER program (Sˇali & Blundell, 1993). Structural
information from MEME motif analysis of the loop sequence
was added to the template (Bailey & Elkan, 1994). The
obtained model was aligned with the deposited structure
(PDB entry 6guv) in PyMOL (version 1.8; Schro¨dinger). The
coordinates of the loop model were added to the crystal
structure and fragments were joined using the VMD AutoPSF
plugin. SymmDock (Schneidman-Duhovny et al., 2005) was
used to reconstruct the dimer conformation.
The stability of the new structure was tested by molecular-
dynamics (MD) simulations in NAMD (Phillips et al., 2005).
The protein structure model was centred in a solvent box built
according to the protein size and padded with at least a 10 A˚
layer of water in every direction. The solvent was modelled
explicitly using TIP3W water molecules. 0.15M KCl was
added to ionize the solvent. The MD simulation was
performed using the CHARMM27 force field (Brooks et al.,
2009) in NAMD. Periodic boundary conditions were applied
in which long-range electrostatic interactions were treated
using the particle mesh Ewald method (Darden et al., 1999)
and the cutoff distance was set to 12 A˚. All simulations were
run as duplicates at a constant temperature of 310 K for at
least 200 ns.
In one of the MD simulations of human PATZ1 BTB, the
flexible loop region in one of the monomers formed an extra
-strand structure. The model was further refined by once
more duplicating this monomer into the dimeric form. This
refinement was processed by taking a frame from the run in
which the root-mean-square deviation (r.m.s.d.) with the
initial structure, excluding the loop, was minimal (3.04 A˚) and
by mirroring the information from the monomer with the
formed secondary structures to the other monomer with
M-ZDOCK (Pierce et al., 2005), recreating the dimer by
symmetry. The stability of the new structure was confirmed by
additional MD simulations (twice, 200 ns each). ModLoop
(Fiser & Sali, 2003) was used to model the coordinates of the
missing residues (70–76) in the zebrafish PATZ1 BTB struc-
ture (PDB entry 6guw) and the stability of the modelled
structure was assessed by MD as before.
3. Results and discussion
3.1. Structural features of the murine and zebrafish PATZ1
BTB domains
Here, we report the crystal structures of the BTB domains
of murine and zebrafish PATZ1 (Fig. 2). In a similar way to
other members of the ZBTB family, both PATZ1 BTB crystal
structures reveal a strand-exchange homodimer, organized as
a core fold BTB domain preceded by an N-terminal extension
that interacts with the partner chain in the dimer. The char-
acteristic secondary structures of the dimerization interfaces
(1–1, A1–A2 and 2–A5) are conserved. Size-exclusion
chromatography data for both the murine and zebrafish BTB
domains suggest that the homodimeric complex is the most
abundant oligomerization state found in solution (Supple-
mentary Fig. S1). The murine PATZ1 BTB domain protein
was expressed from a construct encoding amino acids 12–166
preceded at the N-terminus by 20 amino acids comprising a
His tag and an HRV-3C protease digestion site (Figs. 2a and
2b). The last ten of these amino acids (ALEVLFQGPG) are
visible in the structure and fold into a -strand (0) anti-
parallel to the first N-terminal PATZ1 -strand (1)
(Supplementary Fig. S2). Superposition of this structure with
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Figure 2
Structure of the PATZ1 BTB domain. (a) Crystal structure of the BTB domain of the mouse PATZ1 protein (PDB entry 6guv) in cartoon representation
(front view). The crystallographic asymmetric unit contains a PATZ1 BTB domain monomer (blue) with a second monomer (green) created by
crystallographic symmetry. Secondary structures are indicated in capital and Greek letters. (b) Top view of the mouse PATZ1 BTB domain structure. N-
and C-termini are indicated on one monomer. The coordinates of 31 residues in a central region, unique to mammalian PATZ1 BTB domains, could not
be assigned (indicated by a dotted loop). (c) Crystal structure of the BTB domain of the zebrafish PATZ1 protein (PDB entry 6guw) with individual
monomers coloured yellow and red (front view). (d) Top view of the zebrafish PATZ1 BTB structure. The coordinates of seven residues in the zebrafish
PATZ1 BTB domain could not be assigned (indicated by a dotted loop). (e) Superimposition of the mouse (blue and green) and zebrafish (yellow and
red) PATZ1 BTB domains (r.m.s.d. of 0.62 A˚). ( f ) A space-filling representation of the mouse PATZ1 BTB domain structure. The predicted structure (in
purple) of the central region was generated by homology modelling followed by conformation equilibration using MD simulations. Note that the
modelled structure contains a predicted short -strand. The three conserved degron residues, annotated at the bottom of Fig. 1(b) and predicted to play a
role in BTB dimer degradation, are highlighted in red. Numbering refers to the residues in the crystal structure.
that of BCL6 BTB in complex with co-repressor peptides
(PDB entries 1r2b and 3bim; Ahmad et al., 2003; Ghetu et al.,
2008) suggests that these extra residues structurally mimic the
-strand-forming residues in both SMRT and BCOR
(Supplementary Fig. S3), although their amino-acid sequence
is not conserved. Attempts to crystallize the mouse PATZ1
BTB construct following cleavage of the His tag failed,
suggesting that the extra N-terminal amino acids are likely to
aid the crystallization process in this case.
The mammalian PATZ1 (ZBTB19) protein is predicted to
contain a 31-amino-acid A2/B3 loop (residues 75–105) that is
partially conserved in cKrox (ZBTB15), which sets PATZ1
apart from the other ZBTB family members (Figs. 1a and 1b).
This large loop replaces a shorter amino-acid stretch that
forms a -strand (B3) in other ZBTB family proteins, as
described in detail by Stogios et al. (2005). This loop is glycine-
and alanine-rich and is predicted to be partially disordered;
however, a short -strand is predicted for the last six residues.
The single difference between the human and mouse PATZ1
BTB domains (T91A) is found within this large loop. In the
crystal structure no density could be assigned to the residues
belonging to the A2/B3 loop, suggesting that these amino acids
are partially disordered or flexible.
Interestingly, in the mouse PATZ1 BTB structure a seven-
amino-acid stretch from the C-terminus of an adjacent mole-
cule in the crystal unit cell extends into the region normally
occupied by the B3 -strand in other ZBTB proteins
(Supplementary Fig. S4). This crystallization artefact
presumably aids crystal packing, as the ‘B3 strand mimic’
appears to stabilize the -sheet formed by B1 and B2. To test
this hypothesis, we crystallized a mouse PATZ1 BTB construct
lacking the last seven C-terminal amino acids. The crystals of
this protein diffracted poorly and to lower resolution (3.4 A˚),
showing the same homodimeric BTB domains in a different
crystal packing (data not shown). This suggests that these
seven amino acids were in fact important for stabilizing the
B1–B2 -sheet and for crystal packing (hence the better
diffraction), yet their absence did not encourage the folding of
the A2/B3 loop.
Sequence alignment shows that while the length of the
A2/B3 loop is conserved in all PATZ1 orthologues, it is
conspicuously absent in those from fish and amphibians
(Fig. 1a). The mammalian A2/B3 loop could be an evolutio-
narily acquired insertion sequence encoding an intrinsically
disordered loop (IDL; Fukuchi et al., 2006). To study the
structure of this region in detail, we solved the structure of the
zebrafish PATZ1 BTB domain to a resolution of 1.8 A˚ (Figs. 2c
and 2d). The zebrafish PATZ1 BTB domain was expressed
from a construct encoding amino acids 1–135 preceded at the
N-terminus by 20 amino acids comprising a His tag and an
HRV-3C protease digestion site. The 20 amino acids at the
N-terminus and the first ten residues of the zebrafish PATZ1
BTB domain are not visible in the electron-density map. In
addition, seven amino acids belonging to the A2/B3 loop are
also missing from the electron density. When excluding the
central loop, the murine and zebrafish sequences share 83.7%
identity, whilst the structures can be superimposed with an
r.m.s.d. of 0.62 A˚ (Fig. 2e). The zebrafish BTB domain also has
the same quaternary structure as the mouse BTB domain: a
strand-exchange homodimer. Owing to the absence of the
long disordered A2/B3 loop, the zebrafish PATZ1 BTB
domain is structurally more similar to other ZBTB proteins
than the mammalian PATZ1 BTB domain. The zebrafish
PATZ1 BTB domain also has a seven-amino-acid sequence
between A2 and B3 for which no discernible electron density
could be found. This loop was modelled usingModLoop (Fiser
et al., 2000; Fiser & Sali, 2003; Fig. 3d).
The human and mouse PATZ1 BTB domains have a single
amino-acid difference (T91A). To detail the possible structure
and dynamic behaviour of the A2/B3 loop in human PATZ1
BTB, we performed molecular modelling and molecular-
dynamics simulations (MD). MD simulations lasting 200 ns
indicated that while the overall dimer forms a stable structure,
the A2/B3 loop region is uniquely flexible. The simulations
also suggest that a new -strand could form within this loop
(Figs. 2f and 3c) and that at least ten amino acids within the
modelled loop contribute to the homodimerization interface
(representing 17.5% of the total interface of 57 amino acids).
Interestingly, the -strand that is generated in the simulations
contains the threonine residue that is the only amino acid that
differs between the human and mouse BTB domains. Other
BTB domains such as LRF and MIZ1 also contain flexible
loops in this region (Stogios et al., 2007; Stead et al., 2007). In
the case of MIZ1, the A2/B3 region mediates tetramerization
of its BTB domain, whilst using size-exclusion chromato-
graphy (Supplementary Fig. S1) we found no evidence for
such oligomerization in mouse or zebrafish PATZ1.
3.2. A highly charged and dynamic surface contributes to the
homodimerization interface of the PATZ1 BTB domain
The dimerization interfaces of the mouse and zebrafish
PATZ1 BTB domains are very similar. Using the PIC tool
(Tina et al., 2007), we determined that their crystal structures
contain a single structurally corresponding salt bridge (Arg47–
Glu75 in the mouse protein and Arg36–Glu64 in the zebrafish
protein; the residue numbering refers to the crystal struc-
tures), in addition to the residues engaged in inter-chain
hydrophobic interactions and hydrogen bonds (Figs. 3a and
3b). The interfaces retrieved from PDBePISA (Krissinel &
Henrick, 2007) contain four basic and five acidic residues for
the murine protein and four basic and three acidic residues for
the zebrafish protein (Table 2).
In order to understand the dynamics of these interfaces,
we assessed the number of contact-forming residues in the
energy-minimized modelled BTB domains (Figs. 2f, 3c and
3d). Using the VMD tools, we found a dramatic increase in the
number of charged residues (mostly negative) that participate
in interface contacts (marked with asterisks in Table 2). To
understand the stability of these contacts, we assessed those
that persist above a threshold value (15%) during the lifetime
of the MD simulation (Figs. 3c and 3d). During the simulation,
the A2/B3 loop region significantly contributes to the interface
in both models, resulting in flexibility of the salt bridges that
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form between a single charged amino acid from one monomer
and multiple opposite charged amino acids from the opposite
monomer. While Arg47 of mouse PATZ1 BTB is only engaged
with Glu75 in the crystal structure, MD show that it can
contact a broader number of charged residues, including those
from the flexible loop (Asp50, Asp84 and Asp89; Supple-
mentary Fig. S6). We also find that two of the three degron
residues (annotated in Figs. 1b and 2f) that are predicted to
play a role in BTB heterodimer degradation participate in the
interaction interface of both BTB homodimer structures.
3.3. Co-repressor binding modalities are not conserved in
different BTB domains
BTB domains have been shown to interact with the co-
repressor proteins NCOR1, SMRT and BCOR (Huynh &
research papers
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Figure 3
Identification of residues involved in homodimer interaction interfaces. Contact maps of inter-chain residue interactions of the mouse (a) and zebrafish
(b) PATZ1 BTB domain crystal structures. Hydrophobic interactions (green), hydrogen bonds (blue) and ionic bonds (red) are indicated. The relevant
elements of the secondary structures are shown for orientation. A highly charged dimerization interface mediates PATZ1 BTB homodimerization. (c) A
split homodimer view in surface representation and completed with the modelled loop highlights the residues involved in the interaction interface;
positively (blue) and negatively (red) charged residues are annotated and neutral residues are shown in purple. Inter-chain salt bridges that persist above
the threshold are indicated by straight lines and those that do not persist by dotted lines. (d) The zebrafish PATZ1 dimerization interface is also shown as
a split homodimer view for comparison. Numbering refers to the crystal structure files.
Bardwell, 1998; Wong & Privalsky, 1998; Melnick et al., 2002;
Huynh et al., 2000). Co-repressor binding to the BCL6 BTB
domain requires dimerization because the interaction inter-
face (lateral groove) is formed by residues in both monomers.
23 residues from each BCL6 monomer contribute to this
interface (Ahmad et al., 2003; Fig. 4). Additionally, four resi-
dues, when mutated (L19S, N23H and L25S/R26L), interfere
with co-repressor binding by preventing homodimerization of
the BTB domain (Huynh & Bardwell, 1998; Ghetu et al., 2008;
Granadino-Rolda´n et al., 2014). The PATZ1 BTB domain has
also been shown to bind to NCOR1, suggesting that a similar
lateral groove may be mediating this interaction (Bilic et al.,
2006). In fact, when the residues corresponding to L19S, N23H
and L25S/R26L in BCL6 were mutated in the PATZ1 BTB
domain (L27S, Q33S and R34L), it also failed to bind NCOR1
(Bilic et al., 2006).
Even though BCL6 and PATZ1 are structurally very similar,
their corresponding co-repressor binding interface sequences
are not conserved (Fig. 4d). To examine the structural simi-
larity between the PATZ1 and BCL6 BTB domains, we
calculated the r.m.s.d. (1.56 A˚) between individual monomers.
The structural similarity between BCL6 and PATZ1 was more
evident when the flexible PATZ1 loop was excluded (r.m.s.d.
of 1.23 A˚). Comparison of the surface charge distributions of
the two proteins indicates major differences (Supplementary
Fig. S5). Specifically, the BCL6 lateral groove contains a high
density of positively charged amino acids that interact with the
co-repressors (the interaction with SMRT is shown in Fig. 4a).
Surprisingly, the surface of PATZ1 corresponding to the BCL6
lateral groove did not contain as many basic residues (Fig. 4d
and Supplementary Fig. S5). In fact, this region of mouse and
zebrafish PATZ1 is highly conserved (91% identical) and
contains more acidic amino acids.
The presence of alternatively charged residues in the lateral
groove of PATZ1 may indicate that its interaction with co-
repressors may be through a different mode compared with
BCL6. In this regard, the lateral groove of the PATZ1 BTB
domain is more similar to that of LRF compared with BCL6
(Stogios et al., 2007). We also find that mouse PATZ1 residue
Asp50 (Supplementary Fig. S5) is part of the charged pocket
that is conserved between BCL6, LRF and PLZF (Stogios et
al., 2007). Residue Asp50 in mouse PATZ1, corresponding to
Asp39 in zebrafish and to Asp33 in BCL6, is absolutely
conserved in all ZBTB proteins and happens to be the
previously mentioned second degron residue (Fig. 1). The
charged pocket that is formed by the participation of Asp50
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Table 2
Inter-chain salt bridges in the dimerization interface of the BTB domain of PATZ1.
Residue numbers refer to the crystal structures.
BTB protein PDB code Inter-chain salt bridges Frequency in MD (%)
Intra-monomer salt bridges
Intra-interface All protein
Mouse PATZ1 6guv Glu75–Arg47 (crystal only) 0 Asp50–Arg64 Asp127–Arg42
Asp50–Arg47 (B–A)† 64.84 Asp124–Arg137 Glu111–Arg54†
Asp84–Arg47† 7.54 (BA)–32.77 (AB) Asp84–Arg64† Glu111–Arg110 (B–B)†
Asp89–Arg47 (A–B)† 11.14 Asp94–Arg110† Asp127–Lys43†
Glu158–Arg29† 32.32 (AB)–76.82 (BA) Glu72–Arg154† Glu143–Lys120†
Asp50–Arg110 (A–A)† Asp57–Arg54†
Asp89–Arg64 (A–A)† Asp57–Lys120†
Asp89–Arg110† Asp124–Lys120†
Asp89–Arg47 (B–B)† Glu58–Arg110 (A–A)†
Asp127–Arg133† Glu58–Lys120†
Glu33–Arg29† Glu58–Lys43 (B–B)†
Glu75–Arg64 (A–A)† Glu139–Lys120†
Glu139–Arg137† Asp94–Arg64 (A–A)†
Glu143–Arg137†
Glu158–Arg154†
Glu162–Lys165†
Zebrafish PATZ1 6guw Glu64–Arg36 77.42 (BA)–85.7 (AB) Asp92–Arg105 Asp95–Arg31
Asp39–Lys53 (A–B)† 5.44 Asp33–Arg36† Glu61–Arg122
Asp74–Lys78† 5.89 (AB) Asp39–Lys53† Glu107–Lys88
Glu22–Arg122 (A–B)† 12.84 Asp39–Lys78 (A–A)† Asp33–Lys32†
Glu72–Arg36 (A–B)† 93.06 Asp73–Lys53 (A–A)† Asp92–Arg91†
Glu126–Lys18† 19.08 (AB)–28.42 (BA) Asp92–Lys101 (A–A)† Asp92–Lys88†
Asp95–Lys101† Asp95–Arg91†
Glu22–Lys18† Asp95–Lys32†
Glu22–Arg122 (A–A)† Glu46–Arg43†
Glu72–Lys53† Glu46–Arg91 (A–A)†
Glu107–Arg105† Glu46–Lys88†
Glu47–Arg91†
Glu47–Lys88†
Glu79–Arg43†
Glu79–Lys78†
Glu81–Arg43†
Glu111–Lys88†
Glu126–Arg122 (A–A)†
† Added with MD simulation of the modelled structures.
residues from both monomers has been suggested as an
alternative region for ligand binding (Supplementary Fig. S5;
Melnick et al., 2002).
4. Discussion
A role for PATZ1 has been demonstrated in various malig-
nancies such as thyroid and testicular cancer (Fedele et al.,
2008, 2017; Valentino, Palmieri, Vitiello, Pierantoni et al., 2013;
Chiappetta et al., 2015; Vitiello et al., 2016; Monaco et al.,
2018). The interaction between PATZ1 and the tumour
suppressor p53 (Valentino, Palmieri, Vitiello, Pierantoni et al.,
2013; Valentino, Palmieri, Vitiello, Simeone et al., 2013;
Chiappetta et al., 2015; Keskin et al., 2015) mediated by a motif
in the zinc-finger DNA-binding domain rather than the BTB
domain also links this protein to cancer. Chromosome 22-
specific inversions that translocate the transcription factor
EWSR1 with PATZ1 have been observed in various sarcomas.
While EWSR1 translocates with ETS family proteins in
Ewing’s sarcoma, it potentially encodes two fusion proteins
EWSR1-PATZ1 and PATZ1-EWSR1, the latter of which will
contain the BTB domain (Siegfried et al., 2019; Bridge et al.,
2019; Chougule et al., 2019; Sankar & Lessnick, 2011;
Mastrangelo et al., 2000; Im et al., 2000). The dimerization and
co-repressor interaction properties of PATZ1 identified in this
study may shed light on the mechanism of these sarcomas.
The gene targets of PATZ1 have not been extensively
identified. ChIP-Seq and RNASeq experiments have identi-
fied 187 putative targets (Encode Project Consortium, 2012;
Keskin et al., 2015). Of these targets, roughly half were
upregulated and half were downregulated in the absence of
PATZ1 expression. How many of these genes are direct targets
and how many require the BTB domain for regulation is not
known. The current study only highlights structural motifs that
are likely to play a role in the interaction of the PATZ1 BTB
domain with co-repressor proteins. Yet other interactions may
be involved in the potential role of PATZ1 in gene upregu-
lation.
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Figure 4
Comparison of the lateral grooves of PATZ1 and BCL6 BTB domains. The structures of the BCL6 (PDB entry 1r2b) (a) and the energy-minimized
modelled mouse (b) and zebrafish (c) PATZ1 BTB domains are shown in surface representation viewed from the front and bottom. The surface area of
the residues in the lateral groove of the BCL6 BTB domain is buried upon formation of the BCL6–SMRT complex (Ahmad et al., 2003). The SMRT
peptide binding to the BCL6 lateral groove is shown in cartoon representation in orange. All residues in the lateral groove are labelled for one monomer.
Colours indicate residue type: positively charged, blue; negatively charged, red. All other residues in this region are coloured purple. The positions of the
mutations that affect the binding to the co-repressor peptides in BCL6 and in PATZ1 are indicated in black (references are given in the text). A sequence
alignment of BCL6 and PATZ1 BTB residues located in the lateral groove region is shown in (d). Residues are numbered according to the BCL6 and
mouse PATZ1 structure files, with the charged residues coloured as in (a)–(c). Apart from positions 29 and 40, where the two alternatives are indicated,
mouse and zebrafish PATZ1 contain the same residues in these structurally corresponding positions. Although the residue conservation for BCL6 and
PATZ1 in this region is low, SMRT/NCOR peptides are predicted to bind the BTB domain of PATZ1 in the same region.
Our present study identifies important structural features of
the PATZ1 BTB domain. One unique feature of BTB domains
is their ability to form homodimers as well as heterodimers as
a result of their close structural homology. Dimer formation is
necessary for interaction with co-repressor proteins for both
PATZ1 and BCL6 (Bilic et al., 2006). A lateral groove that
BCL6 uses to bind co-repressors is structurally conserved in
PATZ1 (Fig. 4). However, the discrepancy in charged amino
acids in this groove (Supplementary Fig. S5) may indicate
altered binding modalities and/or affinities for co-repressors.
In fact, a structurally conserved charged pocket has previously
been hypothesized to be involved in ligand interaction
(Stogios et al., 2007). While this charged pocket is surface-
exposed in BCL6, LRF and PLZF structures, the PATZ1 A2/
B3 loop could dynamically gate this site, potentially regulating
ligand interaction.
Another feature that is common to PATZ1 and BCL6 is
their BTB domain-mediated localization to nuclear speckles
(Huynh et al., 2000; Fedele et al., 2000; Franco et al., 2016).
While PATZ1 interacts with the nuclear speckle-resident
ubiquitin ligase RNF4, whether potential post-translational
modifications owing to this interaction affect its stability is not
known (Pero et al., 2002). A recent study identified three BTB
domain degron residues that are surface-exposed preferen-
tially in heterodimers (Mena et al., 2018). The targeting of
these degrons by ubiquitin ligases mediates the proteasome-
dependent degradation of heterodimers over homodimers. It
is not known whether this is a generalizable feature of BTB
domains. Consistent with the stability of homodimers, in the
current study we find that PATZ1 buries two of these three
degron residues in the protein globular structure (Fig. 2f).
The MD simulation shows that alternative contacts are
possible for several charged residues at the homodimer
interface (Table 2). Because a single charged residue can
contact more than one oppositely charged residue (Fig. 3), the
dimer interface may be more resilient to the disruption of
single contacts. Energetically, the presence of alternative salt
bridges may be necessary to accommodate the flexibility of the
central loop whilst retaining the stability of the dimerization
interface. Nevertheless, there are an exceptional number of
unpaired charged surface residues in the murine PATZ1 BTB
domain. Some proteins, for example calmodulin, with large net
surface charges are known to modulate their environment by
redistributing nonspecific ions in the surrounding medium
(Aykut et al., 2013). Such modes of action are utilized to shift
the population of the available conformational states, leading
to fine-tuned functions.
BTB domains are attractive targets for anticancer
compounds. Compounds that prevent homodimerization or
result in the degradation of BCL6 (Kerres et al., 2017) have
been shown to have highly effective cytotoxic activity in B-cell
lymphomas. Because the BTB domains of ZBTB family
proteins all share the same fold, compound specificity requires
the targeting of unique features. The residues in the A2/B3
loop of PATZ1, which are unique among the ZBTB proteins,
are potentially a specific target for this protein (Fig. 1). The
structure of the PATZ1 BTB domain reported in this study
will aid in the development of therapeutics for those human
malignancies that involve PATZ1 and the testing of the
specificity of compounds targeting other BTB domains.
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